
zzso chemotherapy regimens have improved the outlook for cancer patients since the 1970s, but the payment system for cancer chemotherapy has not changed during that time zzso The zzso and zzso approach for reimbursement provides incentives for medical zzso to use expensive medications when less costly alternatives that deliver similar results are zzso Furthermore, the system does nothing to assess how much value society derives from zzso zzso This paper reviews the historical context of zzso and zzso reimbursement and considers the use of clinical pathways and bundled payments, two alternative strategies that are being tried to reward physicians for improving outcomes and reducing the total cost of cancer zzso 

